Lysogene awarded Innovation Passport by the UK MHRA for the GM1-gangliosidosis program (12/20/2021) - Paris, France — 20 December 2021 at 08:00 am CET — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has awarded LYS-GM101 investigational gene therapy an ‘Innovation Passport’ for the treatment of GM1-gangliosidosis under the United Kingdom’s… Continue Reading


WORLDSymposium Annual Meeting (12/29/2021) - WORLDSymposium annual meeting, February 6 - 11, 2022 at the Manchester Grand Hyatt, San Diego, CA Five full days of new discoveries, cutting-edge research, and updates from ongoing studies will be presented by scientists and clinicians from around the globe. This year’s program includes exciting breakthroughs in Basic Science, Translational Research, Clinical Applications and much… Continue Reading


Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy (10/13/2021) - Treatments for Mucopolysaccharidosis IVA (MPS IVA, also called Morquio syndrome type A) by enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are limited in efficacy depending on the age of initiation and clinical phenotype. Thus, this study aims to assess the effects of treatments on MPS IVA patients compared to untreated MPS IVA… Continue Reading

More News

More Events

More Research